A photo of Phillipe Backeljauw.

Philippe F. Backeljauw, MD


  • Consultant, Cincinnati Center for Pediatric and Adult Turner Syndrome Care
  • Consultant, Center for Growth Disorders
  • Professor, UC Department of Pediatrics
I believe in an honest, open and completely transparent dialogue with the patient and family.

About

Biography

I am a pediatric endocrinologist who specifically treats patients with growth disorders and patients with Turner syndrome. I believe in an honest, open and completely transparent dialogue with the patient and family.

During my fellowship training, which involved both patient care and research, I developed my passion for improving the diagnosis and treatment of growth disorders. My mentorship at the University of North Carolina at Chapel Hill with Dr. Judson Van Wyk and Dr. Louis Underwood, two of the “greats” in this field, convinced me that this was the area I would pursue.

I believe in a rational approach to the work-up and management of children with concerns regarding growth and physical development. I adhere to a cost-conscious approach and guide myself first by a detailed history and exam, rather than jumping to nondiscriminatory testing. I also follow a stepwise approach to solving the medical problem, knowing we may not always find a specific cause for the child’s growth problem. This is something parents should always keep in mind.

I am currently on the board of directors of the Pediatric Endocrine Society and the American Board of Pediatrics Endocrinology Subboard. My past research led to the Food and Drug Administration approval of a growth peptide to treat patients with growth hormone resistance (rhIGF-1), and I’m an international expert in the area of growth hormone resistance.

My current research seeks to find better diagnostic approaches to solving problems related to poor childhood growth. We are also evaluating newer methods for the treatment of growth disorders and how to treat novel growth disorders. In addition, I am involved in several research projects related to the comorbidities of Turner syndrome, for which we are serving the largest clinical cohort in the U.S.

I have published more than 100 peer-reviewed manuscripts, more than 100 abstracts and 17 textbook chapters. I’ve also given more than 90 invited presentations at national and international meetings.

In my free time, I love being in nature. I’m active in hiking, cycling, swimming, kayaking and golf. I also like to read nonfiction books related to philosophy and history.

Additional Languages

French, Spanish

Insurance Information

Cincinnati Children's strives to accept a wide variety of health plans. Please contact your health insurance carrier to verify coverage for your specific benefit plan.

View Insurance Information

Publications

Safety and effectiveness of Omnitrope® (somatropin) in PATRO Children: a multi-center, post-marketing surveillance study comparison of US and international cohort data. Backeljauw, P; Kanumakala, S; Loche, S; Schwab, KO; Miller, BS; Levy, R; McCormick, K; Zouater, H; Zabransky, M; Campbell, K. European Journal of Pediatrics. 2022; 181:2367-2378.

Treatment of Short Stature in Aggrecan-deficient Patients With Recombinant Human Growth Hormone: 1-Year Response. Muthuvel, G; Dauber, A; Alexandrou, E; Tyzinski, L; Andrew, M; Hwa, V; Backeljauw, P. Journal of Clinical Endocrinology and Metabolism. 2022; 107:e2103-e2109.

Improving Anxiety Screening in Patients with Turner Syndrome. Alexandrou, E; Corathers, S; Gutmark-Little, I; Casnellie, L; Gerstle, M; Tatum, J; Khoury, J; Backeljauw, P. Hormone Research in Paediatrics. 2022; 95:68-75.

Clinical phenotype and musculoskeletal characteristics of patients with aggrecan deficiency. Alexandrou, E; Dauber, A; Tyzinski, L; Hwa, V; Andrew, M; Kim, H; Elangovan, S; Gubanich, P; Taylor-Haas, JA; Paterno, M; et al. American Journal of Medical Genetics, Part A. 2022; 188:1193-1203.

Evolution and Future of Growth Plate Therapeutics. Allen, DB; Merchant, N; Miller, BS; Backeljauw, PF. Hormone Research in Paediatrics. 2022; 94:319-332.

Increased Prevalence of Beta-Cell Dysfunction despite Normal HbA1c in Youth and Young Adults with Turner Syndrome. Sheanon, N; Elder, D; Khoury, J; Casnellie, L; Gutmark-Little, I; Cernich, J; Backeljauw, PF. Hormone Research in Paediatrics. 2021; 94:297-306.

Age at and indication for diagnosis of Turner syndrome in the pediatric population. Swauger, S; Backeljauw, P; Hornung, L; Shafer, J; Casnellie, L; Gutmark-Little, I. American Journal of Medical Genetics, Part A. 2021; 185:3411-3417.

Long-term safety of growth hormone treatment in childhood: two Large observational studies: nordiNet IOS and ANSWER. L, S; M, P; P, B; JC, B; BS, M; TR, R; A, H; A, P; N, K; J, R. 2021.

Safety and Effectiveness of Recombinant Human Growth Hormone in Children with Turner Syndrome: Data from the PATRO Children Study. Backeljauw, P; Kanumakala, S; Loche, S; Schwab, KO; Pfäffle, RW; Höybye, C; Lundberg, E; Battelino, T; Kriström, B; Giemza, T; et al. Hormone Research in Paediatrics. 2021; 94:133-143.

Long-Term Safety of Growth Hormone Treatment in Childhood: Two Large Observational Studies: NordiNet IOS and ANSWER. Sävendahl, L; Polak, M; Backeljauw, P; Blair, JC; Miller, BS; Rohrer, TR; Hokken-Koelega, A; Pietropoli, A; Kelepouris, N; Ross, J. Journal of Clinical Endocrinology and Metabolism. 2021; 106:1728-1741.

Patient Ratings and Comments

All patient satisfaction ratings and comments are submitted by actual patients and verified by a leading independent patient satisfaction company, NRC Health. Patient identities are withheld to ensure confidentiality and privacy. Only those providers whose satisfaction surveys are administered through Cincinnati Children’s Hospital Medical Center are displayed. Click here to learn more about our survey